People who take anticholinergic drugs, such as antidepressants and antipsychotics, are at a 50% higher risk of dementia.
Despite safety concerns, a new study reveals that there has been no change in the use of benzodiazepines in the elderly from 2001 to 2010.
Politics play an important role in the therapeutic relationship and political disclosure now common for psychotherapists.
A clinical trial finds Prozac no better than placebo for improving repetitive behaviors.
Researchers suggest that because most antidepressant “success” is due to the placebo effect, they may never find a way to predict outcomes.
Prior use of benzodiazepines, such as Xanax, Librium, or Ativan, may increase the risk of treatment-resistant depression (TRD), according to a new study published in The Journal of Nervous and Mental Disease.
Robin Williams had "therapeutic" levels of the tetra-cyclic antidepressant mirtazapine in his blood at the time of his suicide, according to the coroner's report...
Psychiatrists argue that current practice fails to account for the interaction of biological, psychosocial and iatrogenic factors.
A new study found that having been prescribed an antidepressant previously was associated with an increased risk of depressive relapse.
A new review finds that dehumanizing language, including self-dehumanization, is connected to anxiety, depression, and disordered eating.
People who take SSRI antidepressants are twice as likely to have their dental implants fail, according to McGill University researchers. In a press release,...
The majority of children, adolescents and young adults prescribed antipsychotic medications have not been diagnosed with a mental disorder, according to a recent study published in JAMA Psychiatry.
Throughout the past two decades, studies have warned of increased suicide rates in those taking antidepressants, especially in children and adolescents. Researchers also documented...
Despite their finding, the researchers suggest that SSRIs be given to people who do not meet criteria for depression or anxiety.
A recent commentary by Ganesan Venkatasubramanian and Matcheri Keshavan notes that efforts to identify biomarkers in people diagnosed with psychiatric disorders have been overwhelmingly...
Study finds an apparent connection between SSRIs, the most commonly prescribed type of antidepressant, and increased risk of violent crime.
Finnish reseachers report in Schizophrenia Research that antipsychotic use is associated with cognitive and memory impairments. The University of Oulu team studied forty people...
New research published in the August issue of Psychiatric Annals evaluates the results of randomized control trials on the use of various psychotropic drugs for patients diagnosed with borderline personality disorder (BPD). Despite the “American Psychiatric Association’s practice guidelines endorsement of SSRIs as first-line therapies for BPD,” the results of the meta-analysis reveal that pharmacotherapy in BPD is “not supported by the current literature,” and “should be avoided whenever possible.”
In a systematic literature review, researchers from Canada and Japan found that the antipsychotic aripiprazole (Abilify) was significantly and causally related to increased increased...
A new update to the NICE guideline for depression suggests providers discuss long-term, severe antidepressant withdrawal symptoms.
New research counters the long-held assumption that a longer duration of untreated psychosis is associated with worse outcomes.
A new article documents the “flimsy evidence” behind the recent FDA approval of the party drug esketamine for the treatment of depression.
“This is remarkable for drugs that are used to treat depressive symptoms,” write the researchers.
A new article explores Mahi a Atua, an affirming indigenous Māori healing practice which stands in contrast to the Western psychiatric methods typically promoted by the Movement for Global Mental Health.
In a new study, researchers found no evidence of antidepressant group variance, which means that there's no particular group of patients who improve more than others on the drug.